<DOC>
	<DOC>NCT02929290</DOC>
	<brief_summary>The main objective of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics of BPI-9016M in patients with c-Met-dysregulated advanced NSCLC.Biomarkers related to the efficacy of BPI-9016M will be investigated.</brief_summary>
	<brief_title>Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically or cytologically confirmed, locally advanced or metastatic NSCLC patients, who is not suitable for surgery or radiotherapy Evaluable or measurable disease per Response Evaluation Criteria in Solid Tumors(RECIST1.1) Eastern Cooperative Oncology Group (ECOG) performance status of 01 Life expectancy ≥12 weeks Must have evidence of positive cMet protein expression by IHC from either local data or the results of molecular prescreening evaluations. Adequate bone marrow, hepatic, and renal function Patients of child bearing potential must agree to take contraception during the study and for 90 days after the last day of treatment Signed Informed Consent Form Prior or current treatment with a cMET inhibitor or HGFtargeting therapy Confirmed ALK or ROS1 rearrangement Prior treatment with targeting agents (Including EGFR tyrosine kinase inhibitors,VEGFR TKIs etc.) within 14 days or 5 halflife Prior treatment with anticancer agents (Including cytotoxic chemotherapy,radiotherapy, immunotherapy etc.) within 4 weeks Brain/meninges metastases unless asymptomatic, stable and not requiring steroids for maintenance History of interstitial lung disease, druginduced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease, radiological documentation of idiopathic pulmonary fibrosis at baseline; uncontrolled pleural effusion/pericardial effusion Any evidence of severe or uncontrolled systemic diseases, including CTCAE 2 or higher active infection, unstable angina pectoris, congestive cardiac failure and severe liver/renal or metabolic disease Active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV) History of organ transplant; had surgery or severe injury within 4 weeks Uncontrolled hypertension（Systolic blood pressure≥160mmHg and/or diastolic blood pressure≥100mmHg ） Patients unable to swallow orally administered medication, prior surgical procedures affecting absorption. Pregnant (positive pregnancy test) or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>